Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Multiple Sclerosis

  Free Subscription


15.12.2025

1 Ann N Y Acad Sci
1 Ann Neurol
1 BMC Neurol
1 Brain
4 J Neuroimmunol
2 J Neurol
1 J Neurol Neurosurg Psychiatry
2 J Neurol Sci
1 Lancet Neurol
4 Mult Scler
2 PLoS One
1 Rev Neurol (Paris)


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann N Y Acad Sci

  1. YAN W, Jianhong W, Wen J, Linming Z, et al
    Proteome-Wide Mendelian Randomization Implicates Shared Necroptosis-Ferroptosis Effectors in Causal Pathways of Multiple Sclerosis Susceptibility.
    Ann N Y Acad Sci. 2025 Dec 12. doi: 10.1111/nyas.70162.
    PubMed         Abstract available


    Ann Neurol

  2. WAEDE M, Kingo C, Damsbo K, Joergensen MU, et al
    Phenotypic Changes in a Monocyte Cluster with High Interleukin-1 Beta Expression during Long-Term Anti-CD20 Therapy.
    Ann Neurol. 2025;98:1283-1298.
    PubMed         Abstract available


    BMC Neurol

  3. GOTTBERG K, Kierkegaard M, Larsson BJ, Ytterberg C, et al
    Experiences of disease-modifying treatments in patients with multiple sclerosis - a qualitative study.
    BMC Neurol. 2025 Dec 10. doi: 10.1186/s12883-025-04576.
    PubMed         Abstract available


    Brain

  4. BRUMMER T, Fleischer V
    Beyond clinical labels: a molecular-structural framework for multiple sclerosis subtyping.
    Brain. 2025;148:4155-4157.
    PubMed        


    J Neuroimmunol

  5. OREFICE NS, Amoriello R, Maghrebi O, Ballerini C, et al
    Early response in cytokine and miR-124a, -125b, -223 expression to anti-CD20 in Multiple Sclerosis and its animal model - a preliminary analysis.
    J Neuroimmunol. 2025;411:578823.
    PubMed         Abstract available

  6. BIANCO A, Russo R, Cicia A, Marini S, et al
    Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review.
    J Neuroimmunol. 2026;410:578808.
    PubMed         Abstract available

  7. RANIERI G, Chiarugi A, Buonvicino D
    Early exposure of NOD/ShiLtJ mice to Freund's adjuvant prompts delayed, spontaneous progressive encephalomyelitis.
    J Neuroimmunol. 2026;410:578809.
    PubMed         Abstract available

  8. PALMER AL, Wang R, Zonta YR, Bailey ZDJ, et al
    Cytokine and chemokine production by astrocytes is influenced by Cystatin C.
    J Neuroimmunol. 2026;410:578801.
    PubMed         Abstract available


    J Neurol

  9. BSTEH G, Velez Escola L, Hegen H, Lindner E, et al
    Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).
    J Neurol. 2025;273:24.
    PubMed         Abstract available

  10. TEDONE N, Preziosa P, Meani A, Mistri D, et al
    Clinical, functional and cognitive features of late-onset multiple sclerosis.
    J Neurol. 2025;273:14.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  11. TSERIOTIS VS, Arrambide G, Carnero Contentti E, Tur C, et al
    MRI lesion distribution criteria for MS, NMOSD and MOGAD differentiation: a systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2025;97:59-70.
    PubMed         Abstract available


    J Neurol Sci

  12. NICOLELLA V, Varelli M, Fasano S, Cantone E, et al
    Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis.
    J Neurol Sci. 2025;480:125681.
    PubMed         Abstract available

  13. RANGANI F, Nahayati MA, Pahlevan Kakhki M, Aghaee-Bakhtiari SH, et al
    Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis.
    J Neurol Sci. 2025;480:125693.
    PubMed         Abstract available


    Lancet Neurol

  14. PITTOCK SJ
    Multiple sclerosis research in 2025: earlier diagnosis and halting progression.
    Lancet Neurol. 2026;25:20-22.
    PubMed        


    Mult Scler

  15. GOMEZ-FIGUEROA E, Casallas-Vanegas A
    The revised 2024 McDonald diagnostic criteria can solve the misdiagnosis problem in multiple sclerosis: NO.
    Mult Scler. 2025 Dec 13:13524585251396290. doi: 10.1177/13524585251396290.
    PubMed        

  16. RAMANATHAN S, Solomon AJ
    The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis: YES.
    Mult Scler. 2025 Dec 13:13524585251396284. doi: 10.1177/13524585251396284.
    PubMed        

  17. VAN DER WALT A
    'The revised 2024 McDonald criteria can solve the misdiagnosis problem in multiple sclerosis': Commentary.
    Mult Scler. 2025 Dec 13:13524585251396271. doi: 10.1177/13524585251396271.
    PubMed        

  18. BSTEH G, Marti S, Hammer H, Krajnc N, et al
    Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?
    Mult Scler. 2025 Dec 6:13524585251396283. doi: 10.1177/13524585251396283.
    PubMed         Abstract available


    PLoS One

  19. KREITER D, Franken N, Bouweriks D, Knippenberg S, et al
    Spinal cord lesions in relapsing-remitting multiple sclerosis: Prognostic value of intrathecal production of immunoglobulins.
    PLoS One. 2025;20:e0337515.
    PubMed         Abstract available

  20. VESTITO L, Schenone C, Casazza F, Modenesi R, et al
    Impact of anodal tDCS and virtual reality on cognitive dysfunction in patients with Multiple Sclerosis: Protocol of a double blind, randomized, prospective, controlled study.
    PLoS One. 2025;20:e0337405.
    PubMed         Abstract available


    Rev Neurol (Paris)

  21. RIPSMAN D, Tremlett H, Alzahrani A, Makhani N, et al
    Disease modifying treatment of radiologically isolated syndrome: A systematic review of the use, efficacy, effectiveness, and safety.
    Rev Neurol (Paris). 2025 Oct 15:S0035-3787(25)00612.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.